ОбзорГрафикНовостиTraderScreen

Anthera Pharmaceuticals, Inc./  US03674U3005  /

Nasdaq Other OTC
18.12.2024  20:54:49 Изменение - Объем сделки Бид- Предложение- Максимум Минимум
0.0000USD - 125
Оборот: .0001		 -Величина цены спроса: - -Величина цены предложения: - 0.0000 0.0000
GlobeNewswire 23.11.2021 Santhera and ReveraGen Announce Positive Topline Results with Vamorolone after Completion of the VIS...
GlobeNewswire 02.08.2021 Oyster Point Pharma Announces New Chairperson Appointment to Board of Directors
GlobeNewswire 10.09.2020 Opthea Appoints US-Based Non-Executive Director
GlobeNewswire 08.07.2020 Atossa Therapeutics Advances Product Development Programs with Multiple Key Hires in Clinical, Regul...
GlobeNewswire 16.05.2019 Geron Continues to Build Senior Leadership of Its Development Team
GlobeNewswire 22.01.2019 Apollomics, Inc. Strengthens Leadership with Key Hires
GlobeNewswire 31.08.2018 Report: Developing Opportunities within Anthera Pharmaceuticals, NRG Energy, Antares Pharma, El Poll...
GlobeNewswire 22.08.2018 Global Oral Proteins and Peptides Market 2018-2030 - Current Market Landscape of Orally Administrabl...
GlobeNewswire 27.06.2018 Anthera Pharmaceuticals Announces Withdrawal of its Nasdaq Hearing Request and Suspension of Trading...
GlobeNewswire 30.05.2018 AzurRx Announces Appointment of Dr. James Pennington as Chief Medical Officer
GlobeNewswire 16.05.2018 Oral Proteins and Peptides Market, 2030
GlobeNewswire 04.05.2018 New Research: Key Drivers of Growth for Global Medical REIT, DXP Enterprises, SJW, FTI Consulting, A...
GlobeNewswire 19.03.2018 Research Report Identifies Anthera Pharmaceuticals, Hancock Holding, MKS Instruments, Second Sight M...
GlobeNewswire 13.03.2018 World Novel Drugs and Smart Devices for Respiratory Disorders Market, 2030
GlobeNewswire 12.03.2018 Anthera Pharmaceuticals Reports Top Line Data from the RESULT Phase 3 Clinical Study of Sollpura
GlobeNewswire 07.03.2018 Anthera Pharmaceuticals to Present at the 30TH Annual ROTH Conference
GlobeNewswire 06.03.2018 Anthera Pharmaceuticals Deemed Compliant with Nasdaq Listing Criteria
GlobeNewswire 05.03.2018 Anthera Pharmaceuticals Provides Business Update and Reports 2017 Fourth Quarter and Fiscal Year Fin...
GlobeNewswire 08.02.2018 Anthera Pharmaceuticals to Participate in the BIO CEO & Investor Conference and SunTrust Robinson Hu...
GlobeNewswire 05.02.2018 Anthera Concludes Last Patient Visit in the Phase 3 RESULT Clinical Study of Sollpura
GlobeNewswire 25.01.2018 Anthera Receives Positive Nasdaq Listing Determination
GlobeNewswire 22.01.2018 Anthera Announces Positive Outcome of Second Interim Futility Analysis in the Phase 3 RESULT Clinica...
GlobeNewswire 17.01.2018 Report: Exploring Fundamental Drivers Behind Anthera Pharmaceuticals, Alarm, Aptevo Therapeutics, Sh...
GlobeNewswire 09.01.2018 Anthera Pharmaceuticals Announces Second Closing of $15 Million Private Placement Offering
GlobeNewswire 08.01.2018 Anthera Pharmaceuticals Announces Results of Special Meeting of Stockholders